Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu Wakino

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|November 29, 2017
[The clinical characteristics of hypertension in chronic kidney disease.]Shu Wakino
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 24, 2004
[Anti-atherosclerotic effects of PPAR gamma ligands]Shu Wakino
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 9, 2005
[Syndrome of inappropriate secretion of ADH (SIADH)]Koichi Hayashi, Shu Wakino
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 18, 2010
[Anti-atherosclerotic effects by PPARgamma and its ligands through the activation of reverse cholesterol transport system]Shu Wakino, Hiroshi Itoh
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 18, 2018
Aging and kidney diseaseShu Wakino, Hiroshi Itoh
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2005
[Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway]Shu Wakino, Koichi Hayashi
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 20, 2011
[Mitochondrial dysfunction in metabolic syndrome]Shu Wakino, Hiroshi Itoh
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|June 15, 2012
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 6. CKD associated with obesity and metabolic syndrome]Shu Wakino, Hiroshi Otoh
Nihon Jinzo Gakkai Shi|January 9, 2019
[Gut microbiota and chronic kidney disease]Shu Wakino, Ayumi Yoshifuji, Hiroshi Itoh
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 16, 2008
[Obesity in CKD]Hirobumi Tokuyama, Shu Wakino, Hiroshi Ito
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|November 29, 2017
[The clinical characteristics of hypertension in chronic kidney disease.]Shu Wakino
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 24, 2004
[Anti-atherosclerotic effects of PPAR gamma ligands]Shu Wakino
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 9, 2005
[Syndrome of inappropriate secretion of ADH (SIADH)]Koichi Hayashi, Shu Wakino
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 18, 2010
[Anti-atherosclerotic effects by PPARgamma and its ligands through the activation of reverse cholesterol transport system]Shu Wakino, Hiroshi Itoh
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 18, 2018
Aging and kidney diseaseShu Wakino, Hiroshi Itoh
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2005
[Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway]Shu Wakino, Koichi Hayashi
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 20, 2011
[Mitochondrial dysfunction in metabolic syndrome]Shu Wakino, Hiroshi Itoh
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|June 15, 2012
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 6. CKD associated with obesity and metabolic syndrome]Shu Wakino, Hiroshi Otoh
Nihon Jinzo Gakkai Shi|January 9, 2019
[Gut microbiota and chronic kidney disease]Shu Wakino, Ayumi Yoshifuji, Hiroshi Itoh
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 16, 2008
[Obesity in CKD]Hirobumi Tokuyama, Shu Wakino, Hiroshi Ito
Pageof 15